Mode
Text Size
Log in / Sign up
N/A N=145 Treatment

Post Market Study of Parietene™ DS Composite Mesh in Ventral Hernia Repair

Ventral Hernia

Enrolled (actual)
145
Serious AEs
23.2%
Results posted
Nov 2022
Primary outcome: Primary: Number of Participants With Hernia Recurrence Within 12 Months Following Parietene™ DS Composite Mesh Use in Ventral Hernia Repair — 4; 116 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Parietene DS Composite Mesh (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Medtronic - MITG
Primary completion
Jul 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Hernia Recurrence Within 12 Months Following Parietene™ DS Composite Mesh Use in Ventral Hernia Repair
4; 116
SECONDARY
Number of Participants With Incidence of Adverse Device Effects (ADEs) Intra-operatively, at Discharge, Within 1 Month, 3 Months, 12 Months and 24 Months Following Parietene™ DS Composite Mesh Use in Ventral Hernia Repair.
0; 14; 31; 34; 40; 42
SECONDARY
Number of Participants With Incidence of Hernia Recurrence at 1 Month, 3 Months and 24 Months Following Parietene™ DS Composite Mesh Use in Ventral Hernia Repair
0; 0; 4

Summary

A multi-center post-market single arm prospective study of Parietene™ DS Composite Mesh in subjects undergoing ventral hernia repair to confirm its clinical safety and performance in the short (1, 3 months), mid (12 months) and long term (24 months)

Eligibility Criteria

Inclusion Criteria

  • Preoperative Inclusion Criteria
  • Subject has provided informed consent
  • Subject is ≥18 years of age (at the time of consent)
  • Subject is undergoing elective ventral hernia repair (primary or incisional) with intraperitoneal mesh placement

Exclusion Criteria

  • Preoperative Exclusion Criteria
  • BMI > 45 kg/m2
  • Subject is undergoing emergency surgery
  • Subject is pregnant or planning to become pregnant during study participation period
  • Subject is unable or unwilling to comply with the study requirements or follow-up schedule
  • Subject has comorbidities which, in the opinion of the Investigator, will not be appropriate for the study or the subject has an estimated life expectancy of less than 6 months
  • The subject has participated in another investigational drug or device research study within 30 days of enrollment
  • Subject has a parastomal hernia
  • Intra-operative Exclusion Criteria
  • Subject's hernia repair is in a contaminated or infected site (CDC wound class 2-4) as assessed by the Investigator(s)
  • Subject is undergoing "bridging" repair technique with the mesh placed in an "inlay" position
  • Surgeon is unable to completely remove existing mesh from prior surgery
  • Surgeon overlays 2 meshes
  • Subject receives any mesh other than Parietene™ DS composite mesh
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03495154). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search